Development and Validation of a Clinical Model to Predict the Presence of β-Lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer Patients | Zendy

Samuel A. Shelburne | Zendy; Robert E. Lasky | Zendy; Pranoti Sahasrabhojane | Zendy; Jeffrey Tarrand | Zendy; Kenneth V. I. Rolston | Zendy

Open Access

Development and Validation of a Clinical Model to Predict the Presence of β-Lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer Patients

Author(s) -

Samuel A. Shelburne,

Robert E. Lasky,

Pranoti Sahasrabhojane,

Jeffrey Tarrand,

Kenneth V. I. Rolston

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu260

Subject(s) - medicine , bacteremia , viridans streptococci , neutropenia , intensive care medicine , microbiology and biotechnology , streptococcus , antibiotics , bacteria , chemotherapy , genetics , biology

Concern for serious infection due to β-lactam-resistant viridans group streptococci (VGS) is a major factor driving empiric use of an anti-gram-positive antimicrobial in patients with febrile neutropenia. We sought to develop and validate a prediction model for the presence of β-lactam resistance in VGS causing bloodstream infection (BSI) in neutropenic patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research